Effect of Propranolol on Responses to Drug-Related Imagery Scripts

This study is currently recruiting participants.

Verified by National Institute on Drug Abuse (NIDA), May 2008

First Received: May 30, 2008 No Changes Posted

Sponsor:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00688805

Purpose

This study evaluates the effect of propranolol on drug-related memories.

Condition	Intervention	Phase
Cocaine Dependence	Drug: propranolol Drug: placebo	Phase I

Study Type:	Interventional
Study Design:	Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Effect of Propranolol on Responses to Drug-Related Imagery Scripts

Resource links provided by NLM:

Drug Information available for: Propranolol hydrochloride Propranolol Dexpropranolol

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

drug craving [ Time Frame: 1 hr ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

galvanic skin response [ Time Frame: 1 hr ] [ Designated as safety issue: No ]

Estimated Enrollment:	200
Study Start Date:	May 2008
Estimated Primary Completion Date:	June 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: propranolol 40 mg given as a single oral administration in an opaque capsule
2: Placebo Comparator	Drug: placebo matching capsule containing no active medication

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

cocaine use; enrolled in methadone maintenance therapy; age 18-55

Exclusion Criteria:

allergy or hypersensitivity to propranolol; medical or psychiatric disorder that would contraindicate propranolol administration; pregnant or breast feeding; taking medications that would contraindicate propranolol administration

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00688805

Contacts

Contact: Kenzie Preston, Ph.D.

443-740-2326

kpreston@intra.nida.nih.gov

Locations

United States, Maryland
NIDA Intramural Research Program	Recruiting
Baltimore, Maryland, United States, 21224
Contact: Kenzie Preston, Ph 443-740-2326 kpreston@intra.nida.nih.gov

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

More Information

No publications provided

Responsible Party:	National Institute on Drug Abuse ( Kenzie L. Preston, Ph.D., Principal Investigator )
Study ID Numbers:	NIDAIRP433
Study First Received:	May 30, 2008
Last Updated:	May 30, 2008
ClinicalTrials.gov Identifier:	NCT00688805 History of Changes
Health Authority:	United States: Federal Government; United States: Institutional Review Board

Keywords provided by National Institute on Drug Abuse (NIDA):

cocaine
propranolol

Additional relevant MeSH terms:

Cocaine-Related Disorders
Vasodilator Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Physiological Effects of Drugs
Disorders of Environmental Origin
Cardiovascular Agents
Antihypertensive Agents

Pharmacologic Actions
Propranolol
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Adrenergic beta-Antagonists
Adrenergic Antagonists
Anti-Arrhythmia Agents

ClinicalTrials.gov processed this record on February 08, 2010